GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule

finance.yahoo.com/news/gh-research-responds-fda-clinical-112017153.html

In This Article:
GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New Drug/IND Application for GH001.…

This story appeared on finance.yahoo.com, 2025-07-09 11:20:17.
The Entire Business World on a Single Page. Free to Use →